ARCHIVES

In Brief: New Spending Plan Funds NIH At FY95 Level; Continuing Resolution Expires Dec. 15

This article is from The Cancer Letter archive.

Vol. 21 No. 45 | November 24, 1995

Download PDF Visit The Full Archive

Related Articles

Zytiga and Prednisone Extends Overall Survival in mCRPC Trial

October 31, 2014

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

January 25, 2013

Stand Up To Cancer Launches Immunology “Dream Team”

December 14, 2012

Nexavar Improves PFS In HER-2 Negative Breast Cancer

May 27, 2011

In Brief: Ma and Tyner Receive Award From AAAS

July 4, 2014

Human Embryo Panel Defines Acceptable Research For Funding

September 30, 1994